Related references
Note: Only part of the references are listed.Hepatic Clearance, but Not Gut Availability, of Erythromycin Is Altered in Patients With End-Stage Renal Disease
H. Sun et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Identification of Cytochrome P450 Isoforms Involved in the Metabolism of Paroxetine and Estimation of Their Importance for Human Paroxetine Metabolism Using a Population-Based Simulator
Jakob Jornil et al.
DRUG METABOLISM AND DISPOSITION (2010)
Selection of Alternative CYP3A4 Probe Substrates for Clinical Drug Interaction Studies Using In Vitro Data and In Vivo Simulation
Robert S. Foti et al.
DRUG METABOLISM AND DISPOSITION (2010)
Confidence Assessment of the Simcyp Time-Based Approach and a Static Mathematical Model in Predicting Clinical Drug-Drug Interactions for Mechanism-Based CYP3A Inhibitors
Ying-Hong Wang
DRUG METABOLISM AND DISPOSITION (2010)
Pharmacokinetic modeling of the hepatobiliary transport mediated by cooperation of uptake and efflux transporters
Hiroyuki Kusuhara et al.
DRUG METABOLISM REVIEWS (2010)
In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A
Thomas M. Polasek et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut-The effect of diltiazem on the time-course of exposure to triazolam
Karen Rowland Yeo et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2010)
CLINICAL EPIDEMIOLOGY OF CARDIOVASCULAR DISEASE IN CHRONIC KIDNEY DISEASE
Robert N. Foley
JOURNAL OF RENAL CARE (2010)
Population-Based Mechanistic Prediction of Oral Drug Absorption
Masoud Jamei et al.
AAPS JOURNAL (2009)
Assessment of the Impact of Renal Impairment on Systemic Exposure of New Molecular Entities: Evaluation of Recent New Drug Applications
Y. Zhang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Drug Development Perspective on Pharmacokinetic Studies of New Drugs in Patients With Renal Impairment
R. L. Lalonde et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
In vitro-in vivo Extrapolation of Transporter-mediated Clearance in the Liver and Kidney
Hiroyuki Kusuhara et al.
DRUG METABOLISM AND PHARMACOKINETICS (2009)
A Framework for Assessing Inter-individual Variability in Pharmacokinetics Using Virtual Human Populations and Integrating General Knowledge of Physical Chemistry, Biology, Anatomy, Physiology and Genetics: A Tale of 'Bottom-Up' vs 'Top-Down' Recognition of Covariates
Masoud Jamei et al.
DRUG METABOLISM AND PHARMACOKINETICS (2009)
Quantitative Evaluation of Pharmacokinetic Inhibition of CYP3A Substrates by Ketoconazole: A Simulation Study
Ping Zhao et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Utilization of estimated physicochemical properties as an integrated part of predicting hepatic clearance in the early drug-discovery stage: Impact of plasma and microsomal binding
C. Emoto et al.
XENOBIOTICA (2009)
Application of CYP3A4 in vitro data to predict clinical drug-drug interactions;: predictions of compounds as objects of interaction
Kuresh A. Youdim et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Maraviroc:: in vitro assessment of drug-drug interaction potential
Ruth Hyland et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Emerging evidence of the impact of kidney disease on drug metabolism and transport
T. D. Nolin et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Genetic Variants of the Organic Cation Transporter 2 Influence the Disposition of Metformin
I. S. Song et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Pharmacokinetic predictions in children by using the physiologically based pharmacokinetic modelling
F. Bouzom et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2008)
OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine
Zhi-Jun Wang et al.
PHARMACOGENETICS AND GENOMICS (2008)
Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin
T. J. Urban et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP (TM)) predicts in vivo metabolic inhibition
Ashok Rakhit et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Physiologically based approaches towards the prediction of pharmacokinetics:: in vitro-in vivo extrapolation
Stefan S. De Buck et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2007)
Prevalence of chronic kidney disease in the United States
Josef Coresh et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Prediction of intestinal first-pass drug metabolism
Jiansong Yang et al.
CURRENT DRUG METABOLISM (2007)
Model-based drug development
R. L. Lalonde et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Sequential metabolism is responsible for diltiazem-induced time-dependent loss of CYP3A
Ping Zhao et al.
DRUG METABOLISM AND DISPOSITION (2007)
Simulation and prediction of in vivo drug metabolism in human populations from in vitro data
Amin Rostami-Hodjegan et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data:: Reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver
Zoe E. Barter et al.
CURRENT DRUG METABOLISM (2007)
Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis
Sara De Martin et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Role of parathyroid hormone in the downregulation of liver cytochrome P450 in chronic renal failure
Jose Michaud et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Medical progress - Assessing kidney function - Measured and estimated glomerular filtration rate
Lesley A. Stevens et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions
Trudy Rodgers et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2006)
The human intestinal cytochrome P450 pie
MF Paine et al.
DRUG METABOLISM AND DISPOSITION (2006)
Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability
E. M. Howgate et al.
XENOBIOTICA (2006)
Effects of renal failure on drug transport and metabolism
H Sun et al.
PHARMACOLOGY & THERAPEUTICS (2006)
Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro:: Effect of fibrates and rifampicin
LI Kajosaari et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2005)
A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes
RJ Riley et al.
DRUG METABOLISM AND DISPOSITION (2005)
Physiologically based pharmacokinetic modeling 1: Predicting the tissue distribution of moderate-to-strong bases
T Rodgers et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2005)
Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics
M Niemi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Drug dosing in chronic kidney disease
S Gabardi et al.
MEDICAL CLINICS OF NORTH AMERICA (2005)
The epidemiology of chronic kidney disease
RC Atkins
KIDNEY INTERNATIONAL (2005)
Predictive performance of the Modification of Diet in Renal Disease and Cockcroft-Gault equations for estimating renal function
M Froissart et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Performance of the modification of diet in renal disease and Cockcroft-Gault equations health and in chronic kidney in the estimation of GFR in disease
ED Poggio et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Power, selection bias and predictive performance of the population pharmacokinetic covariate model
J Ribbing et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2004)
Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors
NJ Proctor et al.
XENOBIOTICA (2004)
Utility of recombinant enzyme kinetics in prediction of human clearance: Impact of variability, CYP3A5, and CYP2C19 on CYP3A4 probe substrates
A Galetin et al.
DRUG METABOLISM AND DISPOSITION (2004)
Measured and estimated GFR in healthy potential kidney donors
AD Rule et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2004)
Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination
LM Berezhkovskiy
JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
Cytochrome P450 3A expression and activity in the human small intestine
JS Yang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Effects of renal diseases on the regulation and expression of renal and hepatic drug-metabolizing enzymes: a review
HM Korashy et al.
XENOBIOTICA (2004)
CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide
TB Bidstrup et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Drug metabolism in chronic renal failure
V Pichette et al.
CURRENT DRUG METABOLISM (2003)
Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency
MC Chapelsky et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Modeling of intestinal drug absorption: Roles of transporters and metabolic enzymes (for the Gillette Review Series)
KS Pang
DRUG METABOLISM AND DISPOSITION (2003)
Hepatic drug metabolism and transport in patients with kidney disease
TD Nolin et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2003)
The effect of chronic renal failure on hepatic drug metabolism and drug disposition
AW Dreisbach et al.
SEMINARS IN DIALYSIS (2003)
Iron status and hemoglobin level in chronic renal insufficiency
CY Hsu et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2002)
The effects of portal shunts on intestinal cytochrome P450 3A activity
A Rostami-Hodjegan et al.
HEPATOLOGY (2002)
Downregulation of intestinal cytochrome P450 in chronic renal failure
FA Leblond et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2002)
Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution
P Poulin et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2002)
The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil citrate
GJ Muirhead et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Predicting the impact of physiological and biochemical processes on oral drug bioavailability
B Agoram et al.
ADVANCED DRUG DELIVERY REVIEWS (2001)
Effect of chronic renal failure on the expression and function of rat intestinal P-glycoprotein in drug excretion
C Veau et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2001)
Modelling and simulation of variability and uncertainty in toxicokinetics and pharmacokinetics
I Nestorov
TOXICOLOGY LETTERS (2001)
Pharmacokinetics of repaglinide in subjects with renal impairment
TC Marbury et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)